NCT05017116View on ClinicalTrials.gov

A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Chronic Hepatitis B
Interventions
DRUG

RBD1016

subcutaneous injection

DRUG

Placebo

subcutaneous injection

DRUG

Entecavir

Take orally.

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

Suzhou Ribo Life Science Co. Ltd.

INDUSTRY

NCT05017116 - A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) Infection | Biotech Hunter | Biotech Hunter